

Chemical Composition and Effect of Aqueous Extract of *Alpinia Oxyphylla* Miq. on Inhibition of *Salmonella Typhi*

Xiaoyun Zhang¹, Dong Liu^{2*}, Qichang Yang³, Shiyu Jin⁴, Xiaojie Zhou¹

1.Hainan Vocational University of Science and Technology, Haikou, Hainan 570100, China

2.Tongchuan Hengyuan Guangming Pharmaceutical Compnay, Tongchuan, Shaanxi 727000, China

3.Beijing Rehabilitation Hospital Affiliated to Capital Medical University, Beijing 100000, China

4.Huai'an University, Huai'an, Jiangsu 223001, China

*Corresponding author: Dong Liu, 845518225@qq.com

Copyright: 2025 Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0), permitting distribution and reproduction in any medium, provided the original author and source are credited, and explicitly prohibiting its use for commercial purposes.

Abstract: Objective: To investigate the separation and extraction process of the primary chemical constituents of *Alpinia oxyphylla* Miq. against *Salmonella typhi*, and its antibacterial efficacy, providing theoretical basis for novel gastrointestinal epidemic drugs and interventions against pathogen transmission. **Methods:** *Alpinia oxyphylla* Miq.: purified water-to-material ratio 1:5, refluxed at 100°C for 6 hours, repeated three times. *Alpinia oxyphylla* Miq. extract was concentrated by freeze-drying at a 30:1 solid-to-liquid ratio to obtain the final extract. The efficacy of the extraction method and antibacterial activity were assessed using the disk diffusion method. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined to establish the minimum therapeutic thresholds. Gas chromatography-mass spectrometry (GCMS) was employed to identify the primary bioactive constituents and their relative concentrations in the *Alpinia oxyphylla* Miq. aqueous extract. **Results:** The water extract of *Alpinia oxyphylla* Miq. demonstrated potent antibacterial activity against *Salmonella typhi* ($P < 0.001$), with an inhibition zone diameter of 8.43 ± 0.11 mm, MIC of 0.25 g/ml, and MBC of 0.5 g/ml. The extraction process was established as follows: *Alpinia oxyphylla* Miq. : purified water ratio 1:5, reflux heating at 100°C for 6 hours, repeated three times, followed by freeze-drying at 30:1 concentration. This yielded an extract rich in , primarily comprising octadecanoic acid (44.27%), palmitic acid (26.18%), caproic acid (8.15%), 10-hydroxydecanoic acid (7.83%) as the main components, supplemented by 3-hydroxy-dodecanoic acid (1.78%), cis-13-eicosenoic acid (1.58%), valeric acid (1.21%), heptanoic acid (1.13%), nonanoic acid (1.06%), oleic acid (0.87%), and butyric acid (0.47%). **Conclusion:** This extraction process for novel antimicrobial compounds from *Alpinia oxyphylla* Miq. demonstrates high stability, operational feasibility, and precise composition and efficacy. It provides a practical theoretical foundation for developing novel natural medicines against infectious diseases caused by *Salmonella typhi*, while offering further insights for antimicrobial drug development.

Keywords: *Alpinia Oxyphylla* Miq; *Salmonella Typhi*; Extraction; Antibacterial Activity

Published: Nov 13, 2025

DOI: <https://doi.org/10.62177/apjcmr.v1i5.859>

1.Introduction

1.1 Research Background and Importance

Alpinia oxyphylla Miq., also known as Yizhizi or Yizhi, is the dried mature fruit of *Alpinia oxyphylla* Miq. (Zingiberaceae), primarily produced in Guangxi, Yunnan, Hainan, Guangdong, and Fujian provinces. It ranks among the Four Great Southern Medicinal Herbs. It possesses a warm nature and pungent flavour, containing active constituents such as zingerone, kaempferol, euryzine A, euryzine B, and euryzine alcohol. It exhibits effects of warming the spleen to arrest diarrhoea and consolidating essence to reduce urination. It is frequently employed for spleen-cold diarrhoea, abdominal cold pain, excessive salivation, kidney deficiency with enuresis, frequent urination, and seminal emission with turbid discharge. Modern applications include clinical use and fundamental research in diarrhoea, Alzheimer's disease, cancer, kidney disease, and bone disorders^[1-5]. *Salmonella typhi* is one of the most prevalent serotypes within the *Salmonella* genus. As a zoonotic, foodborne pathogen affecting both humans and animals, it evades host immune clearance through immune escape mechanisms, leading to persistent infections that pose a severe threat to human health and public safety^[6-10]. While extensive research exists on chemically synthesised drugs targeting *Salmonella typhi*, these present safety concerns and high production costs. Furthermore, research into natural medicines and bioactive compounds against this pathogen remains underdeveloped, significantly limiting its prevention, control, and treatment. Consequently, exploring novel natural medicines against *Salmonella typhi* infection holds considerable significance.

1.2 Research Objectives

This study employed a common and straightforward liquid solvent heating extraction process to isolate the active components of *Alpinia oxyphylla* Miq. against *Salmonella Typhi*, followed by high-fold concentration. Chemical composition and content analysis were conducted using GCMS. Bacteriostatic activity was evaluated using the zone of inhibition as an efficacy indicator, while MIC and MBC values were determined to establish dose-response relationships. This provides a scientific basis for the development and clinical application of new drugs based on the antimicrobial efficacy of natural products.

2. Materials and Methods

2.1 Materials

Salmonella Typhi CMCC (B) 50071 (Shanghai Luwai), *Alpinia oxyphylla* Miq. (Beijing Tongrentang), 0.22 µm needle filter, McFarland turbidity tubes (Hunan Bickman), Nutrient agar medium, Nutrient broth medium (Jinan Baibo), 204178 - Digital Vernier Caliper (SYNTEK, Germany), SPX-80B Biochemical Incubator (Tianjin Saidelisi), THZ-100 Constant Temperature Shaker Incubator (Shanghai Yetuo), Agilent 7890 B-5977 Gas Chromatography-Mass Spectrometry System (Agilent Technologies, USA), RV 10 auto pro V rotary evaporator (Germany, Eka), 6 mm × 0.7 mm sterile blank antimicrobial susceptibility discs (UK, Oxoid), WP-UPS-10/20 fully automatic water purifier (Sichuan, Watpu).

2.2 Methods

2.2.1 Separation and extraction process for active constituents from *Alpinia Oxyphylla* Miq. Aqueous Extract

Alpinia oxyphylla Miq. was pulverised and sieved through an 80-mesh screen. The powder-to-purified water ratio was 1:5. The mixture was soaked at room temperature for 2 hours, Reflux heated at 100°C for 6 hours, repeated three times. Centrifuged at 10,000 rpm for 1 hour; combine supernatants and freeze-dry at a 30:1 ratio to solidify the test drug. For use, dissolve in purified water to a concentration of 1 g/ml for subsequent experiments.

2.2.2 GCMS Analysis of Bioactive Components in *Alpinia Oxyphylla* Miq. Aqueous Extract

Gas chromatography employed an HP-5MS column (30 m × 0.25 mm × 0.25 µm) with a constant flow rate of 1 mL/min using helium as carrier gas. Column temperature followed the programmed ramping schedule in Table 1. Injection port temperature was 280°C, with a 1 µL injection volume and 2:1 split ratio. Mass spectrometry employed an electron impact ionisation source with an electron energy of 70 eV, an ion source temperature of 220°C, a transfer line temperature of 280°C, and a solvent delay of 3 minutes. Data were acquired in full scan mode over the range of 10–650 amu. GCMS data were analysed using Mass Hunter (VB.07.00) software for compound identification via integration. Search parameters were: SNR (signal-to-noise ratio) 2; Sharpness threshold 25%; Absolute height threshold 500 points; Relative height 0.1%. Automatic library searching utilised the NIST 17 database with a score threshold of 60; absolute height threshold set to 100 points; relative height threshold set to 0.5%.

Table 1: Temperature-programmed conditions

Temperature ramp rate	Temperature	Hold time/min	Hold time
	40	0	0
5	100	3	15
20	300	3	28

2.2.3 Efficacy of *Alpinia Oxyphylla* Miq. Aqueous Extract in inhibiting *Salmonella typhi*

Sterile solution (concentration 1 g/ml) was obtained by passing the solid-state final product aqueous solution through a 0.22 μm needle filter twice. *Salmonella Typhi* was diluted with sterile water to a concentration of 1.5×10^7 cfu. Using a pipette, 20 μL of the bacterial suspension was dropped onto 9 cm nutrient agar plates and spread evenly. A sterile blank antibiotic susceptibility disc (6 mm diameter) was then placed on each plate. A 20 μL pipette volume of sterile drug solution was applied to fully saturate the disc for the treatment group. A purified water group was established as a control using the same method. Both groups were incubated in a 37°C incubator for 24 hours, after which the diameter of the inhibition zone was measured using calipers.

2.2.4 Dose-response relationship of *Alpinia Oxyphylla* Miq. Aqueous Extract in inhibiting *Salmonella typhi*

Dissolve 2 g of the solid final product in 2 mL sterile broth. Filter twice through a 0.22 μm needle filter. Prepare ten dilutions using a half-serial dilution method (initial drug concentration: 1 g/mL). Dilute *Salmonella typhi* in sterile water to a concentration of 1.5×10^8 cfu using sterile water. Pipette 100 μL (neglecting this minute volume) into each group to achieve a bacterial concentration of 1.5×10^7 cfu. Incubate at 37°C for 24 hours, then determine the MIC by observing turbidity. For all clear groups, mix thoroughly, then pipette 20 μL of the suspension onto 9 cm nutrient agar plates, spreading evenly. Incubate the plates at 37°C for 24 hours, then observe colony growth to determine the minimum bacterial concentration (MBC).

2.2.5 Statistical Methods


Statistical analysis was performed using GraphPad Prism 6.01 software. $P < 0.05$ was considered statistically significant.

3. Results

3.1 Inhibitory Effect of *Alpinia Oxyphylla* Miq. Aqueous Extract on *Salmonella Typhi*

The inhibition zone diameter in the treatment group was 8.43 ± 0.11 mm, while that in the control group was 6.04 ± 0.01 mm, demonstrating a significant difference ($P < 0.001$). This indicates that the water extract of *Alpinia oxyphylla* Miq. effectively inhibits *Salmonella Typhi*, as shown in Figure 1.

Figure 1: Statistical diagram of inhibition zones (note: *** $P < 0.001$)



3.2 GCMS Analysis of Bioactive Components in Aqueous Extract of *Alpinia Oxyphylla* Miq.


Analysis revealed four principal fatty acids: octadecanoic acid (44.27%), palmitic acid (26.18%), caproic acid (8.15%), 10-hydroxydecanoic acid (7.83%) as the four principal fatty acids, each constituting over 5% of the total. Additionally, seven minor fatty acids were identified: 3-hydroxy-dodecanoic acid (1.78%), cis-13-eicosenoic acid (1.58%), pentanoic acid (1.21%), heptanoic acid (1.13%), nonanoic acid (1.06%), oleic acid (0.87%), and butanoic acid (0.47%) as seven secondary representative organic acid components. These collectively constitute the anti-*Salmonella typhimurium* system of the water

extract of *Alpinia oxyphylla* Miq., as shown in Table 2 and Figure 2.

Table 2 : GCMS Analysis Results

Name	Molecular Formula	Retention time/min	Peak Area Percentage/%
cis-Vaccenic acid	C18H34O2	22.939	44.27
n-Hexadecanoic acid	C16H32O2	22.073	26.18
Hexanoic acid	C6H12O2	9.063	8.15
10-Hydroxydecanoic acid	C10H20O3	20.904	7.83
3-hydroxy-Dodecanoic acid	C12H24O3	19.814	1.78
cis-13-Eicosenoic acid	C20H38O2	23.66	1.58
Pentanoic acid	C5H10O2	6.091	1.21
Heptanoic acid	C7H14O2	10.903	1.13
Nonanoic acid	C9H18O2	16.466	1.06
Oleic Acid	C18H34O2	24.071	0.87
Butanoic acid	C4H8O2	4.215	0.47

Figure 2 : GCMS base peak chromatogram



3.3 Dose-response Relationship between Aqueous Extract of *Alpinia Oxyphylla* Miq. and *Salmonella Typhi*

MIC and MBC assays yielded MBC at 0.5 g/ml and MIC at 0.25 g/ml, indicating that higher concentrations of *Alpinia oxyphylla* Miq. extract are required to inhibit *Salmonella typhi*, demonstrating a clear dose-response relationship.

Conclusion

Digestive system infections severely impact human health, not only through direct tissue damage caused by pathogens but also through associated complications or comorbidities. The persistent emergence of drug-resistant pathogens and frequent outbreaks place a continuous burden on society and public finances, making the pursuit of more effective, low-toxicity, and economical therapeutic agents crucial [11-16]. Natural products and their derivatives, already successfully applied clinically, offer inherent advantages such as safety, accessibility, high efficacy, and low toxicity, making them ideally suited to address this pressing issue. Therefore, the effective isolation and extraction of antibacterial active components from these sources, coupled with the evaluation of their antimicrobial effects, can lay the theoretical foundation for traditional Chinese medicine in combating digestive system infections.

This study employed a straightforward technique of reflux extraction with water to isolate water-soluble components from *Alpinia oxyphylla* Miq.. Utilising GC-MS omics analysis, it identified a diverse array of antibacterial active constituents, primarily comprising organic acids such as octadecanoic acid, palmitic acid, hexanoic acid, and 10-hydroxydecanoic acid. Organic acid compounds, being common substances with broad sources and high safety profiles, exhibit well-established antibacterial efficacy. Their effectiveness has been demonstrated in studies on digestive system infections such as *Helicobacter pylori* and *Salmonella* [17-19]. The extraction of numerous organic acid compounds in this study provides technical assurance for the practical application of this process route. Furthermore, significant antibacterial activity against *Salmonella typhi* was observed ($P < 0.001$), with an inhibition zone diameter of 8.43 ± 0.11 mm. The minimum inhibitory concentration (MIC) was determined to be 0.25 g/ml, with MBC at 0.5 g/ml. This indicates a positive correlation between inhibitory strength and drug concentration, demonstrating the feasibility of applying this extraction process to typhoid *Salmonella* drug development and providing reference for its rational clinical application.

Funding

Hainan University of Science and Technology Institutional Research Grant (HKKY2024-87); Undergraduate Innovation and Entrepreneurship Training Programme (X202511049398); Undergraduate Innovation and Entrepreneurship Training Programme (X202511049201); Undergraduate Innovation and Entrepreneurship Training Programme (D202504071303298456)

Conflict of Interests

The authors declare that there is no conflict of interest regarding the publication of this paper.

Reference

- [1] Wang, X., Wang, J., Bi, H., et al. (2025). Research progress in the extraction and purification, structural characteristics, pharmacological activities, structure-activity relationships, and applications from *Alpinia oxyphylla* Miq. polysaccharides. *International Journal of Biological Macromolecules*, 315(P1), 144387.
- [2] Yan, Z. J., Zhang, L., Han, X. Y., et al. (2025). *Amomum villosum* and *Saposhnikovia divaricata* modulate NLRP3 inflammasome via the PI3K/Akt/mTOR pathway to alleviate inflammatory responses in diabetic nephropathy mice. *Chinese Journal of Traditional Chinese Medicine*, 50(10), 2798–2809.
- [3] Chengxing, Q., Liping, M., Ji, W., et al. (2023). Sesquiterpenoids from the fruits of *Alpinia oxyphylla* Miq. and their neuroprotective effect. *Phytochemistry*, 211, 113680. (Note: Corrected redundant "Miq." in species name; standardized article number format.)
- [4] Han, M., Wu, S. S., He, X. C., et al. (2025). Effects and mechanisms of salted *Alpinia oxyphylla* Miq. extract on amino acid metabolism in renal Yang deficiency-induced polyuria rats. *Shandong Medicine*, 65(01), 48–52+58.
- [5] Lu, B. T., Zhu, Y. T., Liu, X. N., et al. (2024). Three new sesquiterpene compounds from *Alpinia oxyphylla* Miq. *Acta Pharmaceutica Sinica*, 59(04), 997–1001.
- [6] Yang, Y. F., Wang, L. Y., Zhou, W., et al. (n.d.). Study on the efficacy and mechanism of compound Baituoweng powder in inhibiting *Salmonella Typhimurium* in mice. *Journal of Yangzhou University (Agricultural and Life Sciences Edition)*. <https://kns.cnki.net/kcms/detail/32.1648.S.20250701.1328.004.html> (Note: Online published in press, no final page numbers; accessed July 21, 2025.)
- [7] Farishta, S., Faryal, R., Waqas, M., et al. (2025). Mechanisms of azithromycin resistance in *Salmonella Typhi*: molecular insights from dynamics behaviour to clinical implications. *Journal of Biomolecular Structure & Dynamics*, 1–20. (Note: In press, no final volume/issue.)
- [8] Editorial Office of Chinese Journal of Veterinary Science, & Zhang, J. M. (2025). Research on the mechanism of persistent infection achieved by *Salmonella Typhimurium* secreted proteins through mitochondrial autophagy. *Chinese Journal of Veterinary Science*, 55(06), 847–848.
- [9] Zhou, Q., Yu, Y., Xie, Z., et al. (2025). In vitro and in vivo antibacterial effects of indole-3-lactic acid against *Salmonella enterica* serovar *Typhimurium*. *Food Bioscience*, 68, 106618. (Standardized article number format.)
- [10] Guerra, E. F., Karlinsey, E. J., Libby, J. S., et al. (2025). Evasion of serum antibodies and complement by *Salmonella*

- Typhi and Paratyphi A. PLoS Pathogens, 21(5), e1012917.
- [11] Zhang, M. F., Wen, Q. H., Li, Z. Q., et al. (2024). Changes in gut microbiota following *Clostridium difficile* infection in patients with digestive system diseases. *Chinese Journal of Hospital Infection*, 34(16), 2444–2447.
- [12] Zhang, R., Li, Y., Huang, Y., et al. (2025). Causal relationship between infection and gastrointestinal cancers: a multi-variable Mendelian randomisation study. *Chinese Clinical Oncology*, 14(3), 31.
- [13] He, L., Liang, J., Zhu, X., & Cao, Y. (2025). Study on the effects of *Helicobacter pylori* infection density and antibiotic resistance on pathogen eradication outcomes in peptic ulcer patients. *Chinese Journal of Pathogenic Biology*, 20(06), 715–718+723.
- [14] Wang, Y., Zhou, K., Zhang, Y., et al. (2025). The systemic impact of *Helicobacter pylori* infection on the microbiome of the entire digestive tract based on mucosal, gastric juice, and faecal specimens. *Helicobacter*, 30(3), e70047.
- [15] Cahueque, M., Azmitia, E., & Claudio, R. (2025). Sacral joint infection caused by *Salmonella*: a post-gastroenteritis complication—a case report. *Journal of Medical Case Reports*, 19(1), 315.
- [16] Anbagi, A. U., Saad, A., Ibrahim, T., et al. (2025). *Salmonella typhi* bacteremia with infective fasciitis and psoas abscess: A rare and challenging presentation. *Cureus*, 17(6), e85447.
- [17] Gao, Q., Ma, Y., Liu, H., et al. (2025). A potential anti-*Helicobacter pylori* strategy: Exploring the antibacterial mechanism of organic acids in sea buckthorn (*Hippophae rhamnoides* L.). *Microbiological Research*, 296, 128133. (Standardized article number format.)
- [18] Wen, W., Hu, Y. J., Cheng, H. Z., et al. (2023). Research progress on the regulatory effect of organic acids on pig gut microbiota and its antibacterial mechanism. *Chinese Journal of Animal Science and Veterinary Medicine*, 50(08), 3133–3141.
- [19] Rodríguez, I. A., Antonio, J. V., Pablo, F., et al. (2013). Optimisation of the combined antimicrobial effect of organic acids and temperature on foodborne *Salmonella* and *Escherichia coli* in cattle feed using response surface methodology. *Foodborne Pathogens and Disease*, 10(12), 1030–1036. (Completed missing page number suffix.)